Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.37 |
| ▸ | SCARB1 | Q8WTV0 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6792730 | 0.81 | F10 (0.39) | CCR2MCL1 | |
| Water SCHEMBL6797826 | 0.80 | F10 (0.38) | CCR2MCL1 | |
| SCHEMBL7884466 | 0.76 | KDM4E (0.51) | CCR2MAPTALDH1A1TSHRTP53 | |
| SCHEMBL7947029 | 0.72 | FABP4 (0.49) | CCR2MAPTALDH1A1KMT2A | |
| SCHEMBL7956149 | 0.72 | L3MBTL1 (0.47) | MAPTALDH1A1TSHRCYP1A2CYP2C19 | |
| SCHEMBL28909949 | 0.71 | CCR2 (0.58) | CCR2ALDH1A1CYP1A2MCL1 | |
| SCHEMBL6800245 | 0.70 | F10 (0.47) | MCL1 | |
| SCHEMBL7884672 | 0.69 | F10 (0.49) | CCR2MAPTALDH1A1TSHRCYP1A2 | |
| SCHEMBL10003163 | 0.69 | NOD1 (0.53) | MAPTALDH1A1TSHR | |
| SCHEMBL17224372 | 0.68 | FABP4 (0.57) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6734205-B2 | SODIUM CHANNEL MODERATORS; CARDIOVASCULAR DISORDERS; ANTIDIABETIC AGENTS | SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) | 2004-05-11 | — | — | US | disclosed |
| US-20030018056-A1 | Substituted guanidine derivatives | SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) | 2003-01-23 | — | — | US | disclosed |
| EP-1238971-A1 | SUBSTITUTED GUANIDINE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2002-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018056-A1 | Substituted guanidine derivatives | SLC28A1, SLC7A1, ABCB11 | CCR2 2412/4885MAPT 4395/4885ALDH1A1 1321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.